Development
AbbVie Inc.
ABBV
$191.08
-$1.34-0.70%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -66.76% | -54.98% | 119.05% | -94.68% | -38.85% |
| Total Depreciation and Amortization | -3.76% | 1.36% | 10.14% | 3.60% | 8.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.66% | 1,900.00% | -53.55% | 836.67% | 1,335.29% |
| Change in Net Operating Assets | -47.64% | 76.32% | 147.42% | 35.29% | 178.04% |
| Cash from Operations | -36.01% | -0.37% | 26.25% | -14.57% | 46.36% |
| Capital Expenditure | 3.76% | -23.73% | -24.48% | -8.02% | -13.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -84.33% | -57.00% | 23.44% | -90.81% | 71.83% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -164.62% | -99.55% | -100.62% | 102.33% | -39.25% |
| Cash from Investing | -78.57% | -128.69% | -362.31% | 68.64% | 60.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 73.81% | 99.93% | -50,000.00% | 72.31% | -82.60% |
| Issuance of Common Stock | -41.51% | 227.27% | -31.43% | -49.22% | -29.33% |
| Repurchase of Common Stock | 25.00% | 0.00% | -11.11% | -32.99% | 96.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.79% | -4.91% | -4.71% | -5.34% | -8.30% |
| Other Financing Activities | 82.52% | 80.00% | -43.29% | -28.89% | -50.93% |
| Cash from Financing | 53.82% | 51.78% | -46.32% | 11.19% | -52.00% |
| Foreign Exchange rate Adjustments | 0.00% | 72.88% | 69.70% | 14.29% | 182.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.02% | 36.76% | -15.48% | 31.74% | -8.00% |